Abstract
We describe a technology for generating recombinant polyclonal antibody libraries (PCALs) that enables the creation and perpetuation of standardized mixtures of polyclonal whole antibodies specific for a multiantigen (or polyantigen). Therefore, this technology combines the advantages of targeting multiple antigenic determinants -- high avidity, low likelihood of antigen escape variants, and efficient mediation of effector functions, with the advantages of using monoclonal antibodies -- unlimited supply of standardized reagents and the availability of the genetic material for desired manipulations. The technology for generating recombinant polyclonal antibody libraries begins with the creation of phage display Fab (antibody) libraries. This is followed by selection of sublibraries with desired antigen specificities, and mass transfer of the variable region gene pairs of the selected sublibraries to a mammalian expression vector for generation of libraries of polyclonal whole antibodies. We review her e our experiments for selection of phage display antibody libraries against microbes and tumor cells, as well as the recent literature on the selection of phage display antibody libraries to multiantigen targets.
Keywords: Recombinant polyclonal antibody libraries, Multiantigen, Polyantigen, Fab antibody libraries, PCAls, cDNA synthesis
Combinatorial Chemistry & High Throughput Screening
Title: Recent efforts toward the development of peptide secondary structure mimetics at Molecumetics Ltd. for the discoveries of new drug candidates utilizing combinatorial chemistry with solid phase synthesis are described
Volume: 3 Issue: 3
Author(s): J. Sharon, S. Sarantopoulos, W. Den, C. Y. Kao, C. M. Baecher-Allan, K. E. Santora, S. R. Sompuram, S. Petersen-Mahrt and B. R. Williams
Affiliation:
Keywords: Recombinant polyclonal antibody libraries, Multiantigen, Polyantigen, Fab antibody libraries, PCAls, cDNA synthesis
Abstract: We describe a technology for generating recombinant polyclonal antibody libraries (PCALs) that enables the creation and perpetuation of standardized mixtures of polyclonal whole antibodies specific for a multiantigen (or polyantigen). Therefore, this technology combines the advantages of targeting multiple antigenic determinants -- high avidity, low likelihood of antigen escape variants, and efficient mediation of effector functions, with the advantages of using monoclonal antibodies -- unlimited supply of standardized reagents and the availability of the genetic material for desired manipulations. The technology for generating recombinant polyclonal antibody libraries begins with the creation of phage display Fab (antibody) libraries. This is followed by selection of sublibraries with desired antigen specificities, and mass transfer of the variable region gene pairs of the selected sublibraries to a mammalian expression vector for generation of libraries of polyclonal whole antibodies. We review her e our experiments for selection of phage display antibody libraries against microbes and tumor cells, as well as the recent literature on the selection of phage display antibody libraries to multiantigen targets.
Export Options
About this article
Cite this article as:
Sharon J., Sarantopoulos S., Den W., Kao Y. C., Baecher-Allan M. C., Santora E. K., Sompuram R. S., Petersen-Mahrt S. and Williams R. B., Recent efforts toward the development of peptide secondary structure mimetics at Molecumetics Ltd. for the discoveries of new drug candidates utilizing combinatorial chemistry with solid phase synthesis are described, Combinatorial Chemistry & High Throughput Screening 2000; 3 (3) . https://dx.doi.org/10.2174/1386207003331643
DOI https://dx.doi.org/10.2174/1386207003331643 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Agathokakological Tale of Δ<sup>9</sup>-THC: Exploration of Possible Biological Targets
Current Drug Targets Aliphatic and Aromatic Oxidations, Epoxidation and S-Oxidation of Prodrugs that Yield Active Drug Metabolites
Current Medicinal Chemistry Endothelial Cell Targeted Molecular Imaging in Tumor Angiogenesis: Strategies and Current Status
Current Pharmaceutical Biotechnology Past, Present and Future Therapeutics for Cerebellar Ataxias
Current Neuropharmacology Concomitant use of Tyrosine-Kinase Inhibitor and Mepolizumab in Asthma Secondary to Chronic Myeloid Leukemia with Hypereosinophilia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Thalidomide: An Overview of its Pharmacological Mechanisms of Action
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Bladder Cancer Stem Cells: Biological and Therapeutic Perspectives
Current Stem Cell Research & Therapy Current Status of Thalidomide and CC-5013 in the Treatment of Metastatic Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Diagnosis of Alterations of Serum Calcium Metabolism
Medicinal Chemistry The Immune System of Cancer Patients
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cytokine Therapy for Cancer
Current Pharmaceutical Design Aspirin: A Potential Therapeutic Approach in Pancreatic Cancer
Current Medicinal Chemistry P53 Family: At the Crossroads in Cancer Therapy
Current Medicinal Chemistry Antitumor Activities of Interleukin-27 on Melanoma
Endocrine, Metabolic & Immune Disorders - Drug Targets Cancer Therapy: Targeting Mitochondria and other Sub-cellular Organelles
Current Pharmaceutical Design Functional Evaluation of Neural Stem Cell Differentiation by Single Cell Calcium Imaging
Current Stem Cell Research & Therapy Non Steroidal Anti Inflammatory Drugs As Gatekeepers Of Colon Carcinoma Highlight New Scenarios Beyond Cyclooxygenases Inhibition
Current Cancer Drug Targets RNA Splicing Manipulation: Strategies to Modify Gene Expression for a Variety of Therapeutic Outcomes
Current Gene Therapy Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration
Current Vascular Pharmacology Non-Genotoxic p53-Activators and their Significance as Antitumor Therapy of Future
Current Medicinal Chemistry